Daiichi Sankyo enrolls first patients in mirogabalin clinical trials
Daiichi Sankyo Co., Ltd., said Wednesday that it has enrolled the first patients in its initial large-scale and multinational clinical studies program to assess the efficiency and safety of mirogabalin, an investigational treatment for diabetic peripheral neuropathic (DPNP) and postherpetic neuralgia (PHN). Read More »